AOBiome Therapeutics, Inc. life sciences company focused on transforming human health by developing microbiome-based therapies for local, nasal and systemic inflammatory conditions. AOBiome has a pipeline of multiple, clinical-stage therapeutic candidates
Location: United States, Massachusetts, Cambridge
Employees: 11-50
Total raised: $30M
Founded date: 2013
Investors 2
| Date | Name | Website |
| - | Wild Ventu... | wildventur... |
| - | MBC BioLab... | mbcbiolabs... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 07.01.2017 | - | $30M | - |
Mentions in press and media 11
| Date | Title | Description |
| 21.05.2025 | AOB Pharma reveals new metabolomic insights of B244, suggesting investigation of potential new avenues for treatment | AOBiome's B244 Produces Metabolites Linked to Potential Treatment Areas of Interest AOB Pharma reveals new insights via metabolomic analysis of B244, supporting clinical readouts & suggesting investigation of potential new avenues for t... |
| 09.10.2024 | USPTO Grants AOBiome Therapeutics Composition of Matter Patent for its Clinical Candidate B244 | B244 has demonstrated clinical efficacy on therapeutic indications including: Atopic Dermatitis (Eczema) and Pruritus (Itch), and Acne Vulgaris (Acne) CAMBRIDGE, MA, UNITED STATES, October 9, 2024 /EINPresswire.com/ -- USPTO Grants AOBiome ... |
| 22.10.2019 | Azitra brings in Series A to advance microbiome skin therapies | Azitra has four topical therapies in the pipeline to treat Netherton syndrome, cancer treatment-associated rashes, eczema and ichthyosis vulgaris. Netherton is a chronic, orphan disease caused by a LEKTI protein deficiency. LEKTI regulates ... |
| 26.10.2017 | Bracket acquisition underscores the push to make clinical trials more flexible for patients | Adam Butler, Bracket strategic development and corporate marketing officer, said in an email that mProve has been a BYOD device pioneer and has a track record of working with pharma and regulators to make BYOD work in clinical trials. Also ... |
| 06.01.2017 | Term Sheet — Friday, January 6 | CES, CMO, IPO, CAIO Unicorn Watch: Yesterday I interviewed Xiaomi CFO Shou Zi Chew, formerly a partner at DST Global. Xiaomi, valued at $45 billion, is at CES hoping to deliver on its promise of a broad tech ecosystem offering a variety of ... |
| 05.01.2017 | AOBiome Partners with iCarbonX and Secures $30 Million Investment | Leading microbiome company AOBiome announced it has partnered with iCarbonX, China's largest health data collection and analysis platform. iCarbonX was founded in 2015 by renowned genomicist Jun Wang, whose iCarbonX ecosystem has made a $30... |
| 11.09.2014 | Cola-Flavored Genitals, and Other Potential Uses for Microbiome Hacking | One of the irritating things about Silicon Valley start-ups is their frequent insistence that they're going to save the world, which made talking to Gilad Gome, whose latest venture involves hacking your guts, pretty refreshing. "There... |
| 31.05.2014 | Spray-on bacteria is one company’s surprising idea for curing skin conditions | “My skin began to change for the better. It actually became softer and smoother, rather than dry and flaky, as though a sauna’s worth of humidity had penetrated my winter-hardened shell. And my complexion, prone to hormone-related breakouts... |
| - | Azitra brings in Series A to advance microbiome skin therapies | Connecticut-based microbiome therapy company Azitra recently announced a $14 million haul in Series A funding. The round was led by KdT Ventures and previous investor Bios Partners, along with Godfrey Capital and Connecticut Innovations. Az... |
| - | Spray-on bacteria is one company’s surprising idea for curing skin conditions | In medicine, the microbiome is most often associated with the gut. But there are millions of bacteria, viruses and fungi that live on our skin and in our glands, too, and scientists suspect that learning more about them could lead to better... |
Show more